Passa al contenuto
Merck

A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein.

Cell reports (2021-05-13)
Nikki M McCormack, Mahlet B Abera, Eveline S Arnold, Rebecca M Gibbs, Scott E Martin, Eugen Buehler, Yu-Chi Chen, Lu Chen, Kenneth H Fischbeck, Barrington G Burnett
ABSTRACT

Spinal muscular atrophy (SMA) is a debilitating neurological disorder marked by degeneration of spinal motor neurons and muscle atrophy. SMA results from mutations in survival motor neuron 1 (SMN1), leading to deficiency of survival motor neuron (SMN) protein. Current therapies increase SMN protein and improve patient survival but have variable improvements in motor function, making it necessary to identify complementary strategies to further improve disease outcomes. Here, we perform a genome-wide RNAi screen using a luciferase-based activity reporter and identify genes involved in regulating SMN gene expression, RNA processing, and protein stability. We show that reduced expression of Transcription Export complex components increases SMN levels through the regulation of nuclear/cytoplasmic RNA transport. We also show that the E3 ligase, Neurl2, works cooperatively with Mib1 to ubiquitinate and promote SMN degradation. Together, our screen uncovers pathways through which SMN expression is regulated, potentially revealing additional strategies to treat SMA.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Anti-β-actina monoclonale, clone AC-15, purified from hybridoma cell culture
Sigma-Aldrich
Anti-β-Tubulin II antibody, Mouse monoclonal, clone 7B9, purified from hybridoma cell culture